Quanterix (QTRX) Expected to Post Earnings on Thursday

Quanterix (NASDAQ:QTRX) will likely be releasing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.25) per share and revenue of $37.4620 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.12. Quanterix had a negative return on equity of 23.92% and a negative net margin of 71.86%.The business had revenue of $35.90 million during the quarter, compared to analysts’ expectations of $36.84 million.

Quanterix Stock Down 3.2%

QTRX opened at $3.38 on Thursday. The company has a 50-day moving average price of $3.57 and a 200 day moving average price of $4.39. The company has a market cap of $159.23 million, a PE ratio of -1.43 and a beta of 1.04. Quanterix has a twelve month low of $2.39 and a twelve month high of $8.77.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Royal Bank of Canada raised its holdings in shares of Quanterix by 26.3% during the first quarter. Royal Bank of Canada now owns 170,745 shares of the company’s stock valued at $1,112,000 after buying an additional 35,509 shares during the last quarter. AQR Capital Management LLC boosted its holdings in shares of Quanterix by 204.4% during the first quarter. AQR Capital Management LLC now owns 98,990 shares of the company’s stock worth $644,000 after purchasing an additional 66,470 shares during the period. Goldman Sachs Group Inc. lifted its position in Quanterix by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 349,696 shares of the company’s stock worth $2,277,000 after buying an additional 59,655 shares in the last quarter. Jane Street Group LLC increased its position in Quanterix by 4.2% in the 1st quarter. Jane Street Group LLC now owns 58,313 shares of the company’s stock worth $380,000 after purchasing an additional 2,366 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Quanterix by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 887,080 shares of the company’s stock worth $5,900,000 after purchasing an additional 21,210 shares during the last quarter. Hedge funds and other institutional investors own 86.48% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Weiss Ratings cut Quanterix from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 13th. Wall Street Zen raised Quanterix from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Canaccord Genuity Group reduced their price objective on Quanterix from $8.00 to $4.00 and set a “hold” rating for the company in a research note on Monday, April 20th. Finally, TD Cowen lowered their price objective on shares of Quanterix from $7.00 to $4.00 and set a “hold” rating on the stock in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $4.00.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.